Terry Sweet
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Terry Sweet
Terry Sweet has been an executive and non-executive director of several listed companies for more than 30 years. These companies include XRF Scientific where he was managing director for 4 years, Western Biotechnology, Heartlink, and Scientific Services. Originally trained as a chemist, his interests and expertise now lie in the area of development and supervision of a culture of board integrity, commensurate with technology commercialisation. Mr Sweet is a Fellow of the Australian Institute of Company Directors.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 499th | XRF Scientific | 12% | 54% |
| 511th | Matrix Composites & Engineering | 11% | -0% |
| 575th | Finbar Group | 6% | 0% |
| 1840th | MCS Services | -79% | -7% |
| 1848th | Vonex | -80% | -34% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 57th |  | XRF Scientific | $55.2m |
| 59th | | Matrix Composites & Engineering | $47.4m |
| 60th | | Vonex | $47.2m |
| 62nd |  | MCS Services | $38.6m |
| 63rd | | Finbar Group | $35.8m |
201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| REMUNERATION UPDATE: Non-Executive Chair, Proteomics International Laboratories | 02 Nov 2020 |
| REMUNERATION UPDATE: Non-Executive Chair, Proteomics International Laboratories | 24 Aug 2020 |
| REMUNERATION UPDATE: Non-Executive Chair, Proteomics International Laboratories | 30 Jun 2020 |
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Non-Executive Chair | | 2014 - 2021 | 136 |
| Managing Director | | 2007 - 2012 | 57 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Proteomics International Laboratories | 29 Mar 2018 | Issued | 1,250,000 | $0.20 | $250,000 | Exercise of options |
| Proteomics International Laboratories | 29 Mar 2018 | Other | 1,250,000 | $0.20 | $250,000 | Exercise of options |
| Proteomics International Laboratories | 23 Mar 2018 | Other | 1,133,875 | OtherOff-market transfer | ||
| Proteomics International Laboratories | 16 Mar 2018 | Other | 375,000 | OtherOff-market transfer | ||
| Proteomics International Laboratories | 28 Dec 2016 | Bought | 50,000 | $0.24 | $12,000 | OtherParticipation in share purchase plan |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 12/11/14 | Proteomics International Laboratories | Initial public offering | $4.0m | >> |
